Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)

Complete title: A Phase 1/2, Open-Label, Multicenter, Dose-Escalation and Dose Expansion Study of NKTR-214 and Anti-PD-L1 (Atezolizumab) or Anti-PD-1 (Nivolumab, Pembrolizumab) in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

Research Study Number 20162818
 
Principal Investigator Scott Tykodi, MD
 
Phase I/II

Research Study Description

This study is to determine first, the recommended Phase 2 dose of NKTR-214 when administered in combination with nivolumab, and then, the clinical benefit, safety, and tolerability of combining NKTR-214 with nivolumab in select patients with melanoma, renal cell carcinoma or non-small cell lung cancer. Both drugs target the immune system and may act synergistically to promote anti-cancer effects.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20162818
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Breast Cancer; Kidney Cancer; Lung Cancer; Melanoma; Renal Cancer; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic; Urogenital Neoplasms; Urologic Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Neoplasms, Respiratory Tract; Neoplasms, Thoracic

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials